A carregar...
Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects
AIMS: We conducted a phase I placebo-controlled trial with two i.v. doses (0.5 mg h−1 and 3 mg h−1) of S 18326, a selective thrombin inhibitor that interacts with the catalytic site of thrombin, with the aim to study the relationships between increasing plasma levels of S 18326 and changes in coagul...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Science, Ltd
2002
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1874285/ https://ncbi.nlm.nih.gov/pubmed/11851638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.0306-5251.2001.01534.x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|